CoChat

Association of the CFH Y402H Polymorphism with the 1-Year Response of Exudative AMD to Intravitreal Anti-VEGF Treatment in the Brazilian Population

Medina, Flavio Mac Cord, Motta, Augusto Alves Lopes da, Takahashi, Walter Yukihiko, Carricondo, Pedro Carlos, Motta, Mario Martins dos Santos, Melo, Monica B., Vasconcellos, Jose Paulo C. · 2019 · Ophthalmic Research

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Abstract

Aim: Evidence of the relationship between the polymorphism of the complement factor H (CFH) gene at position 402 (Y402H) and the response to the treatment of wet AMD is controversial. The aim of this study was to compare the functional and morphological 1-year evolution of patients with exudative AMD treated with antivascular endothelial growth factor (VEGF) drugs with the CFH Y402H polymorphism in the Brazilian population. Methods: Forty-six patients treated for wet AMD with bevacizumab or ranibizumab in a pro re nata regimen were included. The evolution of best-corrected visual acuity (BCVA) and central retinal thickness (CRT), and the number of injections over 1 year of follow-up were correlated with CFH genotypes. Results: The analysis of variance for the difference between the BCVA denoted as log MAR (logarithm of the minimum angle of resolution) values showed an improvement at 1 year when compared to baseline (p = 0.039). Profile contrast analysis showed that this difference was significant only in the group without the C allele (p = 0.049), without significance in patients presenting with the risk allele (p = 0.241). CRT showed a mean reduction at 1 year compared to baseline (p < 0.001). Significant differences in the profile contrast test were found in the group without the C allele (p < 0.001) and in patients with the risk allele (p = 0.002). No difference was found in the number of injections among the different groups (p = 0.787). Conclusions: The presence of the risk allele of the Y402H polymorphism in the CFH gene was related to a less favorable evolution over 1 year in this sample of the Brazilian population with exudative AMD who were being treated with anti-VEGF drugs. In agreement with similar previous studies, this study concludes that the CFH risk genotypes may affect the disease response to treatment.

Overview

Integrity signals

Registry

Crossref · 10.1159/000475995

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 27 references

Cited by

See all 12

Metadata

Authors
Medina, F. M. C., Motta, A. A. L. D., Takahashi, W. Y., Carricondo, P. C., Motta, M. M. D. S., Melo, M. B., & Vasconcellos, J. P. C.
Affiliations
Universidade de São Paulo (BR)
Venue
Ophthalmic Research
Publisher
S. Karger AG
Published
2017-06-23
Volume
61
Issue
3
Pages
168-173
ISSN
  • 0030-3747 (ISSN-L)
  • 1423-0259
OpenAlex
W2704667116
Cited by
12
References
27
Citations by year
2024: 1 · 2023: 1 · 2022: 4 · 2021: 1 · 2019: 2 · 2018: 3
FWCI
1.34
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Ophthalmic Research (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
  • Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
  • Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
Keywords
complement factor H, CFH Y402H polymorphism, neovascular age-related macular degeneration, anti-VEGF therapy, bevacizumab, ranibizumab, treatment response, genetic susceptibility, best-corrected visual acuity, central retinal thickness, Brazilian population
MeSH terms
Bevacizumab, Ranibizumab, Aged, Alleles, Brazil, Female, Humans, Male, Pharmacogenetics, Retrospective Studies, Visual Acuity, Complement Factor H, Angiogenesis Inhibitors, Polymorphism, Single Nucleotide, Tomography, Optical Coherence, Vascular Endothelial Growth Factor A, Wet Macular Degeneration, Intravitreal Injections, Genotyping Techniques

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Association of the CFH Y402H Polymorphism with the 1-Year Response of Exudative AMD to Intravitreal Anti-VEGF Treatment in the Brazilian Population. https://app.cochat.ai/papers/10.1159/000475995
The paper
Medina, F. M. C., Motta, A. A. L. D., Takahashi, W. Y., Carricondo, P. C., Motta, M. M. D. S., Melo, M. B., & Vasconcellos, J. P. C. (2019). Association of the CFH Y402H Polymorphism with the 1-Year Response of Exudative AMD to Intravitreal Anti-VEGF Treatment in the Brazilian Population. Ophthalmic Research. https://doi.org/10.1159/000475995

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.